Annual Accounts Receivable
$1.56 B
+$121.20 M+8.40%
31 December 2023
Summary:
Vertex Pharmaceuticals Incorporated annual accounts receivable is currently $1.56 billion, with the most recent change of +$121.20 million (+8.40%) on 31 December 2023. During the last 3 years, it has risen by +$678.00 million (+76.58%). VRTX annual accounts receivable is now at all-time high.VRTX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$1.75 B
+$94.50 M+5.71%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated quarterly accounts receivable is currently $1.75 billion, with the most recent change of +$94.50 million (+5.71%) on 30 September 2024. Over the past year, it has increased by +$211.90 million (+13.77%). VRTX quarterly accounts receivable is now -2.38% below its all-time high of $1.79 billion, reached on 31 March 2024.VRTX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRTX Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +8.4% | +13.8% |
| 3 y3 years | +76.6% | +59.1% |
| 5 y5 years | +281.6% | +294.9% |
VRTX Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +76.6% | -2.4% | +59.1% |
| 5 y | 5 years | at high | +281.6% | -2.4% | +294.9% |
| alltime | all time | at high | >+9999.0% | -2.4% | >+9999.0% |
Vertex Pharmaceuticals Incorporated Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.75 B(+5.7%) |
| June 2024 | - | $1.66 B(-7.6%) |
| Mar 2024 | - | $1.79 B(+14.7%) |
| Dec 2023 | $1.56 B(+8.4%) | $1.56 B(+1.6%) |
| Sept 2023 | - | $1.54 B(-1.1%) |
| June 2023 | - | $1.56 B(+0.5%) |
| Mar 2023 | - | $1.55 B(+7.3%) |
| Dec 2022 | $1.44 B(+26.9%) | $1.44 B(+4.1%) |
| Sept 2022 | - | $1.39 B(+3.9%) |
| June 2022 | - | $1.33 B(+3.1%) |
| Mar 2022 | - | $1.29 B(+13.7%) |
| Dec 2021 | $1.14 B(+28.4%) | $1.14 B(+3.3%) |
| Sept 2021 | - | $1.10 B(+18.4%) |
| June 2021 | - | $929.14 M(-5.0%) |
| Mar 2021 | - | $977.55 M(+10.4%) |
| Dec 2020 | $885.40 M(+39.8%) | $885.40 M(+11.8%) |
| Sept 2020 | - | $791.92 M(+0.0%) |
| June 2020 | - | $791.77 M(-6.3%) |
| Mar 2020 | - | $845.27 M(+33.4%) |
| Dec 2019 | $633.52 M(+54.6%) | $633.52 M(+42.9%) |
| Sept 2019 | - | $443.31 M(-4.6%) |
| June 2019 | - | $464.90 M(+6.1%) |
| Mar 2019 | - | $438.30 M(+7.0%) |
| Dec 2018 | $409.69 M(+45.6%) | $409.69 M(+7.9%) |
| Sept 2018 | - | $379.75 M(-3.5%) |
| June 2018 | - | $393.44 M(+20.2%) |
| Mar 2018 | - | $327.29 M(+16.3%) |
| Dec 2017 | $281.34 M(+40.4%) | $281.34 M(+6.8%) |
| Sept 2017 | - | $263.49 M(+6.3%) |
| June 2017 | - | $247.95 M(+19.2%) |
| Mar 2017 | - | $207.96 M(+3.8%) |
| Dec 2016 | $200.36 M(+15.3%) | $200.36 M(+10.0%) |
| Sept 2016 | - | $182.23 M(-3.8%) |
| June 2016 | - | $189.36 M(+4.1%) |
| Mar 2016 | - | $181.88 M(+4.6%) |
| Dec 2015 | $173.84 M(+128.8%) | $173.84 M(+5.2%) |
| Sept 2015 | - | $165.27 M(+74.9%) |
| June 2015 | - | $94.52 M(+17.7%) |
| Mar 2015 | - | $80.33 M(+5.8%) |
| Dec 2014 | $75.96 M(-11.2%) | $75.96 M(-33.5%) |
| Sept 2014 | - | $114.31 M(+39.7%) |
| June 2014 | - | $81.84 M(+36.7%) |
| Mar 2014 | - | $59.86 M(-30.0%) |
| Dec 2013 | $85.52 M(-40.3%) | $85.52 M(-28.9%) |
| Sept 2013 | - | $120.28 M(-27.0%) |
| June 2013 | - | $164.87 M(-15.0%) |
| Mar 2013 | - | $194.05 M(+35.5%) |
| Dec 2012 | $143.25 M | $143.25 M(+2.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2012 | - | $139.63 M(-24.8%) |
| June 2012 | - | $185.62 M(-20.1%) |
| Mar 2012 | - | $232.23 M(+26.8%) |
| Dec 2011 | $183.13 M(+1361.7%) | $183.13 M(-58.9%) |
| Sept 2011 | - | $445.66 M(+364.2%) |
| June 2011 | - | $96.02 M(+1616.4%) |
| Mar 2011 | - | $5.59 M(-55.4%) |
| Dec 2010 | $12.53 M(+30.5%) | $12.53 M(+152.4%) |
| Sept 2010 | - | $4.96 M(+39.9%) |
| June 2010 | - | $3.55 M(-55.0%) |
| Mar 2010 | - | $7.88 M(-18.0%) |
| Dec 2009 | $9.60 M(-59.1%) | $9.60 M(-5.6%) |
| Sept 2009 | - | $10.17 M(-31.1%) |
| June 2009 | - | $14.76 M(-11.6%) |
| Mar 2009 | - | $16.70 M(-28.9%) |
| Dec 2008 | $23.49 M(-25.0%) | $23.49 M(+6.9%) |
| Sept 2008 | - | $21.97 M(+43.0%) |
| June 2008 | - | $15.37 M(-38.1%) |
| Mar 2008 | - | $24.82 M(-20.7%) |
| Dec 2007 | $31.32 M(-50.2%) | $31.32 M(-9.6%) |
| Sept 2007 | - | $34.66 M(-6.8%) |
| June 2007 | - | $37.19 M(-15.7%) |
| Mar 2007 | - | $44.10 M(-29.9%) |
| Dec 2006 | $62.92 M(+205.5%) | $62.92 M(+47.7%) |
| Sept 2006 | - | $42.61 M(-76.8%) |
| June 2006 | - | $183.67 M(+672.4%) |
| Mar 2006 | - | $23.78 M(+15.5%) |
| Dec 2005 | $20.59 M(+73.2%) | $20.59 M(-0.8%) |
| Sept 2005 | - | $20.76 M(+48.9%) |
| June 2005 | - | $13.94 M(+28.3%) |
| Mar 2005 | - | $10.87 M(-8.6%) |
| Dec 2004 | $11.89 M(+62.4%) | $11.89 M(+40.2%) |
| Sept 2004 | - | $8.48 M(-14.7%) |
| June 2004 | - | $9.94 M(+25.2%) |
| Mar 2004 | - | $7.94 M(+8.4%) |
| Dec 2003 | $7.32 M(-44.5%) | $7.32 M(-6.7%) |
| Sept 2003 | - | $7.85 M(-19.2%) |
| June 2003 | - | $9.72 M(-18.5%) |
| Mar 2003 | - | $11.93 M(-9.7%) |
| Dec 2002 | $13.20 M(-34.9%) | $13.20 M(+0.8%) |
| Sept 2002 | - | $13.10 M(-27.4%) |
| June 2002 | - | $18.06 M(+25.9%) |
| Mar 2002 | - | $14.34 M(-29.2%) |
| Dec 2001 | $20.27 M(-40.2%) | $20.27 M(-43.6%) |
| Sept 2001 | - | $35.92 M(+327.0%) |
| June 2001 | - | $8.41 M(+10.5%) |
| Mar 2001 | - | $7.62 M(-77.5%) |
| Dec 2000 | $33.91 M(+469.3%) | $33.91 M(+469.3%) |
| Dec 1999 | $5.96 M | $5.96 M |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual accounts receivable?
- What is the all time high annual accounts receivable for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual accounts receivable year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly accounts receivable year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual accounts receivable?
The current annual accounts receivable of VRTX is $1.56 B
What is the all time high annual accounts receivable for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual accounts receivable is $1.56 B
What is Vertex Pharmaceuticals Incorporated annual accounts receivable year-on-year change?
Over the past year, VRTX annual accounts receivable has changed by +$121.20 M (+8.40%)
What is Vertex Pharmaceuticals Incorporated quarterly accounts receivable?
The current quarterly accounts receivable of VRTX is $1.75 B
What is the all time high quarterly accounts receivable for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly accounts receivable is $1.79 B
What is Vertex Pharmaceuticals Incorporated quarterly accounts receivable year-on-year change?
Over the past year, VRTX quarterly accounts receivable has changed by +$211.90 M (+13.77%)